Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Evaluation of Elesclomol Sodium and Weekly Paclitaxel in the Treatment of Recurrent or Persistent Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer

NCT00888615 is registered in ClinicalTrials.gov with GOG Foundation as lead sponsor.

NCT NCT00888615
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00888615 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Evaluation of Elesclomol Sodium and Weekly Paclitaxel in the Treatment of Recurrent or Persistent Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Lead sponsor
GOG Foundation
Phase
Phase 2
Overall status
Completed
Start date
December 13, 2010
Completion date
August 31, 2016
Enrollment
58 (actual)
Sites
163

Conditions

As the registry lists them; a condition with its own page is linked.

fallopian tube clear cell adenocarcinoma, fallopian tube endometrioid adenocarcinoma, fallopian tube mucinous adenocarcinoma, fallopian tube serous adenocarcinoma, fallopian tube transitional cell carcinoma, fallopian tube undifferentiated carcinoma, ovarian brenner tumor, ovarian clear cell adenocarcinoma, ovarian endometrioid adenocarcinoma, ovarian mucinous adenocarcinoma, ovarian seromucinous carcinoma, ovarian serous adenocarcinoma, ovarian transitional cell tumor, ovarian undifferentiated carcinoma, primary peritoneal serous adenocarcinoma, recurrent fallopian tube carcinoma, recurrent ovarian carcinoma, recurrent primary peritoneal carcinoma